RevolKa Secures $1.7M Series A Extension to Fuel AI-Driven Protein Engineering

Series A Extension Funding: RevolKa, a Tokyo-based biotech firm, secured an additional $1.7 million in Series A funding, co-led by D3 and DEEPCORE.
Expansion of Drug Discovery Efforts: The new funds will support RevolKa’s expansion in drug discovery and development, focusing on AI-driven protein engineering for therapeutic and industrial applications.
Rare Disease Program Progress: RevolKa recently launched a drug discovery program targeting rare diseases, with some candidates showing positive in vitro proof-of-concept.

Accelerated Drug Discovery: The additional funding will enable RevolKa to expedite its AI-driven drug discovery initiatives, potentially bringing novel therapies to market faster.
Focus on Rare Diseases: RevolKa’s commitment to addressing rare diseases could lead to significant advancements in treatments for conditions that currently lack effective therapies.
Strategic Industry Growth: This funding supports the continued growth of biotech innovations in Japan, particularly in AI-powered protein engineering, positioning RevolKa as a key player in the field.
Strengthened R&D Capabilities: With laboratories in Sendai and expanded resources, RevolKa is well-positioned to enhance its research and development capabilities.
Increased Investor Confidence: The successful funding round, led by notable investors, reflects growing confidence in RevolKa’s technology and strategic direction.

Eksentricity